The Weekly Five | 2–8 November

Five studies worth your time this week, spanning lung SBRT, brain metastases, thoracic reirradiation, AI contouring and prostate dose escalation.

1. SABR associated with higher three-year mortality than surgery in early-stage NSCLC

In 12,546 patients with early-stage NSCLC, adjusted three-year mortality was 30.3% after SABR versus 21.6% after surgery. The national target trial emulation supports surgery for fit patients, but residual confounding remains possible.

Read post

2. STEP phase II reports 100% six-month local control after preoperative brain metastasis radiotherapy

In 63 patients completing preoperative stereotactic RT and surgery, six-month local control was 100%, with 7% radiation necrosis at one year. These encouraging results lack a randomized postoperative RT comparator.

Read post

3. RETHO reports no grade 4–5 toxicity after high-dose thoracic reirradiation

In 60 selected patients receiving radical thoracic reirradiation, grade 3 toxicity occurred in 16.7%, with no reported grade 4–5 events. Two-year local control was 53%, while cumulative lung V20 and mean dose were associated with pneumonitis.

Read post

4. Randomized trial finds no efficiency gain from AI-assisted head and neck tumor contouring

In an 83-patient randomized study, AI-assisted GTV contouring did not reduce initial contouring or multidisciplinary review time. Primary tumor contours required comparable editing, while nodal contours showed a possible increase in corrections.

Read post

5. TARGET achieves 98.5% three-year control within focal prostate boost volumes

In localized prostate cancer, MRI-guided focal VMAT or HDR brachytherapy boosts achieved 98.5% three-year control within treated lesions among 66 evaluable patients. Four additional recurrences occurred outside the boost, highlighting the importance of target definition.

Read post

That's the week. See you next Sunday.

Browse more research Suggest a correction